Clinic
Sunnyside Community Hospital Association
Sunnyside Community Hospital Association was paid $55.09M by Medicaid between Jan 2018 and Dec 2024, across 334 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoSUNNYSIDE COMMUNITY HOSPITAL ASSOCIATION
SUNNYSIDE, WA 98944
SUNNYSIDE, WA 98944
33aNPI1225033814assigned 06/20/2005
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$55.09M
24GClaims743,024
24DCodes billed334
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Washington
Rank by total paid#1 of 31
Median peer was paid$338K
This provider vs. median163×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MATHIESEN, MATHEW controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 113,185 | $7.55M | |
| 2019 | 120,452 | $8.67M | |
| 2020 | 95,821 | $6.98M | |
| 2021 | 94,802 | $6.06M | |
| 2022 | 109,190 | $8.03M | |
| 2023 | 120,700 | $10.58M | |
| 2024incomplete | 88,874 | $7.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 18,779 | 17,139 | $5.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 33,638 | 31,210 | $5.79M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 3,914 | 3,359 | $2.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 7,645 | 6,707 | $2.57M |
| G0378 | Hospital observation service, per hour | 3.8% | 4,392 | 2,242 | $2.09M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 3,738 | 2,913 | $1.51M |
| 80053 | Comprehensive metabolic panel | 2.6% | 31,687 | 26,168 | $1.43M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 9,718 | 9,219 | $1.28M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 38,252 | 30,833 | $1.10M |
| 80050 | General health panel | 1.8% | 8,185 | 7,883 | $1.00M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.6% | 517 | 487 | $861K |
| 73610 | 1.4% | 2,833 | 2,472 | $774K |
322 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 4,834 | $768K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.4% | 4,159 | $759K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,476 | $742K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 5,474 | $705K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.2% | 2,950 | $664K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 8,372 | $660K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 7,982 | $653K |
| 73630 | 1.1% | 2,609 | $588K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,702 | $539K |
| 73110 | <1% | 1,897 | $507K | |
| 73562 | <1% | 2,648 | $479K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 577 | $470K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,970 | $440K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,334 | $436K |
| 73130 | <1% | 1,475 | $418K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 533 | $412K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,464 | $411K |
| 80061 | Lipid panel | <1% | 7,399 | $403K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,856 | $393K |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,336 | $383K |
| 84484 | <1% | 7,286 | $382K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,574 | $379K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,065 | $365K |
| 81025 | <1% | 6,446 | $360K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,058 | $359K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,411 | $355K |
| 76801 | <1% | 1,790 | $348K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,380 | $340K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,484 | $333K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,586 | $331K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,500 | $314K |
| 83690 | <1% | 8,822 | $303K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,169 | $295K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,702 | $292K |
| 74018 | <1% | 2,914 | $279K | |
| 81001 | <1% | 17,663 | $274K | |
| 84439 | <1% | 4,748 | $265K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,353 | $258K |
| 72100 | <1% | 1,782 | $253K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,794 | $243K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,946 | $238K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 534 | $220K |
| 80306 | <1% | 3,615 | $213K | |
| 83880 | <1% | 3,496 | $212K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,998 | $210K |
| 73030 | <1% | 1,581 | $201K | |
| 82728 | <1% | 3,732 | $192K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,254 | $190K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,101 | $176K |
| 73080 | <1% | 593 | $169K | |
| 84702 | <1% | 2,886 | $168K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,419 | $165K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,186 | $165K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,001 | $165K |
| 87186 | <1% | 3,947 | $162K | |
| 87070 | <1% | 3,173 | $153K | |
| 83735 | <1% | 5,549 | $143K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,497 | $143K |
| 76536 | <1% | 551 | $136K | |
| 92567 | <1% | 4,359 | $134K | |
| 83540 | <1% | 4,101 | $133K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,309 | $132K |
| 73140 | <1% | 1,426 | $131K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 162 | $128K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,536 | $128K |
| 82607 | <1% | 3,186 | $125K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,529 | $124K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,461 | $124K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,766 | $124K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,753 | $120K |
| 83550 | <1% | 3,418 | $119K | |
| 85610 | <1% | 4,907 | $118K | |
| 76770 | <1% | 398 | $117K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,244 | $115K |
| 87081 | <1% | 2,585 | $109K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,176 | $103K |
| 86140 | <1% | 3,330 | $103K | |
| 96376 | <1% | 2,192 | $99K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,476 | $96K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,919 | $95K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,593 | $94K |
| 87040 | <1% | 2,597 | $88K | |
| 92523 | <1% | 332 | $87K | |
| 76830 | Ultrasound, transvaginal | <1% | 782 | $86K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,560 | $85K |
| 85379 | <1% | 1,504 | $84K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 113 | $82K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,915 | $82K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,951 | $80K |
| 87807 | <1% | 1,242 | $79K | |
| 82570 | <1% | 1,382 | $74K | |
| 85652 | <1% | 3,031 | $74K | |
| 87077 | <1% | 2,034 | $70K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 729 | $70K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 492 | $68K |
| 92557 | <1% | 1,182 | $67K | |
| 86850 | <1% | 2,398 | $66K | |
| 85730 | <1% | 3,052 | $65K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,327 | $64K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,455 | $64K |
| 81003 | <1% | 3,647 | $63K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,758 | $63K |
| 87400 | <1% | 1,249 | $62K | |
| 83605 | <1% | 2,266 | $61K | |
| 76376 | <1% | 1,263 | $59K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 324 | $58K |
| 73502 | <1% | 514 | $57K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,054 | $57K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 69 | $56K |
| 88304 | <1% | 835 | $55K | |
| 86900 | <1% | 2,871 | $53K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,073 | $53K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 624 | $52K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,260 | $51K |
| 92555 | <1% | 847 | $50K | |
| 64721 | <1% | 66 | $50K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,272 | $50K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,959 | $48K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,729 | $48K |
| 87205 | <1% | 2,783 | $48K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,183 | $47K |
| 92582 | <1% | 400 | $46K | |
| 87088 | <1% | 1,218 | $44K | |
| 86803 | <1% | 1,249 | $42K | |
| 85027 | <1% | 1,527 | $42K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,050 | $42K |
| 86038 | <1% | 1,082 | $41K | |
| 82746 | <1% | 1,257 | $40K | |
| 73590 | <1% | 187 | $39K | |
| 84145 | <1% | 361 | $39K | |
| 84480 | <1% | 640 | $39K | |
| 92587 | <1% | 728 | $38K | |
| 92579 | <1% | 540 | $37K | |
| 72141 | <1% | 50 | $37K | |
| 94642 | <1% | 842 | $37K | |
| 76641 | <1% | 219 | $36K | |
| 84030 | <1% | 630 | $35K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 253 | $35K |
| 86701 | <1% | 915 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 739 | $34K |
| 74019 | <1% | 139 | $33K | |
| 86003 | <1% | 121 | $33K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,503 | $33K |
| 86780 | <1% | 954 | $32K | |
| 71250 | <1% | 114 | $31K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 953 | $30K |
| 97161 | <1% | 541 | $30K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,159 | $30K |
| 82150 | <1% | 856 | $29K | |
| 84403 | <1% | 363 | $28K | |
| 84703 | <1% | 517 | $28K | |
| 72040 | <1% | 214 | $28K | |
| 93971 | <1% | 171 | $27K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,816 | $27K |
| 87340 | <1% | 818 | $27K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,306 | $27K |
| 83970 | <1% | 324 | $25K | |
| 87481 | <1% | 286 | $24K | |
| 87535 | <1% | 185 | $23K | |
| 82043 | <1% | 689 | $22K | |
| 64483 | <1% | 100 | $21K | |
| 80305 | <1% | 284 | $20K | |
| 73560 | <1% | 176 | $20K | |
| 90715 | <1% | 386 | $20K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,781 | $19K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 416 | $18K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 23 | $18K |
| 12001 | <1% | 138 | $18K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 199 | $18K |
| 96367 | <1% | 446 | $17K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 216 | $17K |
| 93970 | <1% | 58 | $17K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 17 | $17K |
| 82533 | <1% | 396 | $16K | |
| 84156 | <1% | 442 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,681 | $15K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 246 | $15K |
| 70486 | <1% | 28 | $15K | |
| 87147 | <1% | 630 | $14K | |
| 87420 | <1% | 255 | $14K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,877 | $13K |
| 85007 | <1% | 1,019 | $13K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 105 | $13K |
| 86376 | <1% | 191 | $12K | |
| 84550 | <1% | 400 | $12K | |
| 92552 | <1% | 172 | $11K | |
| 84153 | <1% | 137 | $11K | |
| 84165 | <1% | 293 | $10K | |
| 86480 | <1% | 127 | $10K | |
| 82550 | <1% | 350 | $10K | |
| 83615 | <1% | 432 | $10K | |
| 86800 | <1% | 354 | $9K | |
| 86762 | <1% | 406 | $9K | |
| 84481 | <1% | 156 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 853 | $8K |
| 82951 | <1% | 141 | $8K | |
| 74022 | <1% | 30 | $8K | |
| 83516 | <1% | 146 | $8K | |
| 80069 | <1% | 116 | $8K | |
| 87045 | <1% | 227 | $7K | |
| 82784 | <1% | 94 | $7K | |
| 82077 | <1% | 135 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 67 | $7K |
| 80179 | <1% | 64 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 101 | $6K |
| 84146 | <1% | 90 | $6K | |
| 94060 | <1% | 66 | $6K | |
| 87511 | <1% | 286 | $6K | |
| 76870 | <1% | 20 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $6K |
| 87538 | <1% | 185 | $5K | |
| 97602 | <1% | 209 | $5K | |
| 82270 | <1% | 183 | $5K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 23 | $5K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 495 | $5K |
| 72070 | <1% | 26 | $5K | |
| 80143 | <1% | 51 | $5K | |
| 83001 | <1% | 62 | $5K | |
| 86901 | <1% | 193 | $4K | |
| 84157 | <1% | 104 | $4K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 359 | $4K |
| 81015 | <1% | 428 | $4K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 26 | $4K |
| 97162 | <1% | 75 | $4K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 110 | $4K |
| 86200 | <1% | 42 | $4K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 285 | $3K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 412 | $3K |
| A9270 | Non-covered item or service | <1% | 4,336 | $3K |
| 84450 | <1% | 102 | $3K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 380 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 269 | $3K |
| 84155 | <1% | 275 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 391 | $3K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 331 | $3K |
| C1763 | Connective tissue, non-human (includes synthetic) | <1% | 16 | $3K |
| 86431 | <1% | 60 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 104 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 238 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 115 | $3K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 283 | $3K |
| 83013 | <1% | 12 | $3K | |
| 82010 | <1% | 150 | $3K | |
| 87338 | <1% | 30 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 155 | $2K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 187 | $2K |
| 11043 | <1% | 41 | $2K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 55 | $2K |
| 86592 | <1% | 107 | $2K | |
| 86787 | <1% | 57 | $2K | |
| 76000 | <1% | 29 | $2K | |
| 86778 | <1% | 17 | $2K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 17 | $2K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 140 | $2K |
| 97166 | <1% | 29 | $2K | |
| 76775 | <1% | 12 | $2K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 787 | $2K |
| 82803 | <1% | 57 | $2K | |
| 82009 | <1% | 136 | $2K | |
| 84100 | <1% | 68 | $2K | |
| 73090 | <1% | 15 | $2K | |
| 96368 | <1% | 36 | $2K | |
| 97164 | <1% | 47 | $2K | |
| 87075 | <1% | 34 | $2K | |
| 82272 | <1% | 78 | $1K | |
| 99205 | Prolong outpt/office vis | <1% | 13 | $1K |
| 36416 | <1% | 245 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 86 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 154 | $1K |
| 84402 | <1% | 15 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 61 | $1K |
| 82950 | <1% | 37 | $1K | |
| 82785 | <1% | 33 | $1K | |
| 59025 | Fetal non-stress test | <1% | 16 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 253 | $968.62 |
| 86702 | <1% | 18 | $936.47 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 68 | $932.65 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,073 | $920.46 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 93 | $901.39 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 46 | $887.64 |
| 99219 | <1% | 12 | $800.70 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 21 | $750.88 |
| 83010 | <1% | 27 | $706.16 | |
| 97032 | <1% | 32 | $671.49 | |
| 87177 | <1% | 14 | $655.33 | |
| 94726 | <1% | 14 | $653.40 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 16 | $643.84 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 739 | $596.44 |
| 92553 | <1% | 13 | $593.40 | |
| 86593 | <1% | 156 | $574.23 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 191 | $532.41 |
| 94729 | <1% | 14 | $502.50 | |
| 86777 | <1% | 17 | $486.15 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 33 | $459.05 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 60 | $439.17 |
| 85045 | <1% | 25 | $416.06 | |
| 84436 | <1% | 16 | $414.54 | |
| 97116 | <1% | 13 | $410.19 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 107 | $366.10 |
| 86430 | <1% | 12 | $342.90 | |
| 20610 | <1% | 20 | $334.74 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 85 | $330.25 |
| 87209 | <1% | 14 | $309.57 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 20 | $308.83 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 56 | $296.90 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 74 | $256.50 |
| 80320 | <1% | 201 | $241.22 | |
| 80329 | <1% | 68 | $235.62 | |
| 81002 | <1% | 116 | $235.08 | |
| 11721 | <1% | 24 | $196.41 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 153 | $157.20 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 15 | $142.40 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | <1% | 20 | $130.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $102.78 |
| 88738 | <1% | 14 | $99.30 | |
| V5266 | Battery for use in hearing device | <1% | 27 | $86.39 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $53.77 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,963 | $0.00 |
| 85060 | 0% | 26 | $0.00 | |
| 99406 | 0% | 43 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHIESEN, MATHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| SHC Medical Center Toppenish | Toppenish, WA | $15.10M |
| SHC Medical Center - Yakima | Yakima, WA | $6.93M |
| SHC Medical Center Toppenish | Union Gap, WA | $4.99M |
| Sunnyside Community Hospital Association | Prosser, WA | $2.35M |
| SHC Medical Center Toppenish | Zillah, WA | $663K |
| SHC Medical Center Toppenish | Toppenish, WA | $381K |
| Sunnyside Community Hospital Association | Union Gap, WA | $316K |
| Sunnyside Community Hospital | Yakima, WA | $51K |
| SHC Medical Center - Yakima | Yakima, WA | $11K |
| Sunnyside Community Hospital | Sunnyside, WA | $4K |
| Sunnyside Community Hospital | Sunnyside, WA | $860.66 |
| Sunnyside Community Hospital Association | Yakima, WA | $839.86 |
| Sunnyside Community Hospital Association | Union Gap, WA | $696.97 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.